ACRS vs. RVPH, MIST, HOOK, ASRT, VTVT, CMRX, ONCY, GNLX, PRPH, and QTTB
Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Reviva Pharmaceuticals (RVPH), Milestone Pharmaceuticals (MIST), Hookipa Pharma (HOOK), Assertio (ASRT), vTv Therapeutics (VTVT), Chimerix (CMRX), Oncolytics Biotech (ONCY), Genelux (GNLX), ProPhase Labs (PRPH), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical preparations" industry.
Aclaris Therapeutics (NASDAQ:ACRS) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.
Aclaris Therapeutics received 361 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 88.89% of users gave Reviva Pharmaceuticals an outperform vote while only 66.96% of users gave Aclaris Therapeutics an outperform vote.
Reviva Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -283.15%. Aclaris Therapeutics' return on equity of -64.56% beat Reviva Pharmaceuticals' return on equity.
Reviva Pharmaceuticals has lower revenue, but higher earnings than Aclaris Therapeutics. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aclaris Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.
Aclaris Therapeutics presently has a consensus price target of $22.25, indicating a potential upside of 1,536.03%. Reviva Pharmaceuticals has a consensus price target of $16.33, indicating a potential upside of 410.42%. Given Aclaris Therapeutics' higher possible upside, equities analysts clearly believe Aclaris Therapeutics is more favorable than Reviva Pharmaceuticals.
In the previous week, Aclaris Therapeutics had 3 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 1 mentions for Reviva Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 0.65 beat Reviva Pharmaceuticals' score of 0.50 indicating that Aclaris Therapeutics is being referred to more favorably in the media.
98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 5.5% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 31.8% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Aclaris Therapeutics beats Reviva Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Aclaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclaris Therapeutics Competitors List
Related Companies and Tools
